Blue city proposes bill to place menstrual products in men's bathrooms
City council members in Maryland introduced a bill Monday to expand access to menstrual products in all city-run bathrooms, including those designated for men.
Baltimore Councilman Paris Gray, who is the lead sponsor of the bill, introduced the legislation during the city council's bi-monthly meeting.
Gray said the bill is not just a proposal, but it reflects the city's commitment to menstrual equity and the values Baltimore holds dear, including dignity, accessibility and public health.
"Access to menstrual products should be as fundamental as access to soap or toilet paper," Gray said. "It is an essential part of personal hygiene, and yet, for far too many people, these products remain out of reach. Menstrual products are not a luxury. They are a necessity, and the absence of access can create undue stress and hardship."
California School District Informs Parents Period Products Are In Bathrooms For 'Any Student Who Menstruates'
Gray said the bill, if approved, will require all city-owned and leased buildings with public restrooms to provide menstrual products, free of charge.
Read On The Fox News App
"This includes restrooms and all kinds of facilities, whether they are designated for men, women, family use or single occupancy," he said.
But the bill, Gray noted, is nothing new. Instead, the bill codifies what Mayor Brandon Scott's administration and Department of General Services have already done by taking steps to ensure menstrual products are available in many public facilities across the city.
California Requires Menstrual Products In Public Schools
Gray also said Baltimore is not joining a national movement for menstrual equality, but instead, is leading the charge across the country.
"Cities and municipalities are recognizing the point-importance of free access to menstrual products and Baltimore's proudly taking this place at the forefront of this critical effort," he said.
Gray did not respond to Fox News Digital's request for comment on the matter.
In February, the Long Beach Unified School District in California took similar measures when it notified parents in an email that all schools containing grades 3 through 12 would have menstrual products in girls bathrooms, all-gender bathrooms, and in at least one boys bathroom.
Emerson College Adds Period Products To Men's Restrooms, Meeting Group's Demand For 'Menstrual Equality'
The email told parents and caregivers the system is "committed to reducing barriers to learning and fostering a supportive environment for all students."
The availability of period products in girls bathrooms and at least one boys bathroom is to "ensure that any student who menstruates-including transgender boys and nonbinary students-can access these necessary products with dignity and discretion," per the email.
In California, the "Menstrual Equality for All Act" was passed in October 2023, and it mandated that changes must be enacted at or before the start of the 2024-25 school year.
The following text was added to the state's education code when the bill was passed:
"On or before the start of the 2024–25 school year, a public school, including a school operated by a school district, county office of education, or charter school, maintaining any combination of classes from grades 3 to 12, inclusive, shall stock the school's restrooms at all times with an adequate supply of menstrual products, available and accessible, free of cost, in all women's restrooms and all-gender restrooms, and in at least one men's restroom."
Menstrual products were defined in the bill as pads and tampons specifically "for use in connection with the menstrual cycle."
The bill also said it is the state legislature's intent "to promote period equity through adequate access to menstrual products in schools also serving grades 3 to 5, inclusive."
Fox News Digital's Elizabeth Pritchett contributed to this report.Original article source: Blue city proposes bill to place menstrual products in men's bathrooms
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Psychedelics as potential mental health treatment are explored by Trump administration
The Trump administration has expressed interest in exploring psychedelics for their potential in treating PTSD and other debilitating mental health issues, various officials have shared. "The Department shares the goal of ensuring that all Americans — especially our nation's veterans — have access to safe and effective treatments for conditions such as PTSD, addiction and depression," a spokesperson for the U.S. Department of Health and Human Services (HHS), run by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital. "Secretary Kennedy is committed to applying rigorous, evidence-based science to research efforts aimed at addressing these serious health challenges." Fda Approves First Ai Tool To Predict Breast Cancer Risk In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin ("magic mushrooms") to treat mental health disorders. MDMA is not approved for clinical use by the U.S. Food and Drug Administration (FDA), but can be studied in clinical settings. Read On The Fox News App Psilocybin is listed as a Schedule I substance under the Controlled Substances Act, which means it has "a high potential for abuse, [is not] currently accepted for medical use in treatment in the United States, and [has] a lack of accepted safety for use under medical supervision." Psilocybin-assisted therapy, however, is legal in Oregon, Colorado and New Mexico. Psychedelic medicines are "showing real promise," according to Dr. Luke Twelves, general practitioner and vice president of medical for Lindus Health in London. Clinical trials have found such treatments safe and effective for patients battling serious mental health issues, according to Twelves. Common Supplements And Medications Could Cause Liver Damage, Studies Show "Take psilocybin, for example — it's demonstrating remarkable results for severe depression that hasn't responded to other medications," he told Fox News Digital. "MDMA is showing similar breakthroughs for PTSD treatment." Clinical trials are also investigating how psychedelics could help with end-of-life anxiety, addiction, eating disorders, chronic pain and OCD, he added. Researchers have faced challenges in terms of regulatory hurdles and proper placebo controls, Twelves said. "Given that these treatments could transform [the] lives of people suffering from conditions where nothing else has worked effectively, it's crucial that we complete this research properly," he said. "The goal is to bring safe, proven psychedelic therapies to the patients who need them most." At President Trump's May 1 cabinet meeting, Department of Veterans Affairs Secretary Doug Collins said that "we're opening up the possibility of psychedelic treatment." Retired Army Sergeant Jonathan Lubecki recently told Fox News' Alexandria Hoff that MDMA stopped his PTSD while he was participating in a clinical trial. "[I] took my first dose of MDMA. I've only taken it three times as part of the clinical trial, haven't taken it since, and haven't found the need to take it since, because I haven't had PTSD," he said. Peter Kasperowicz, Department of Veterans Affairs press secretary, told Fox News Digital the department is safely exploring all avenues that promote the health of veterans. Fallujah Vet Turns Medal Of Heroism Into A Healing Mission For Fellow Warriors With Service Dogs Program "Preliminary findings have produced positive results on psychedelic-assisted therapies for treating mental health conditions," he said. The VA is currently running 11 clinical trials in various phases, with a total of some 800 veterans expected to participate. "The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depressive disorder, major depressive disorder and potentially other mental health conditions," said Kasperowicz. An MDMA study published in the Jan. 2025 issue of The American Journal of Psychiatry found that the substance is "unlike classical psychedelics." The study noted, "MDMA allows the individual to maintain intact ego functioning and a greater degree of cognitive and perceptual lucidity while still experiencing a prosocial altered state of consciousness that facilitates deeply emotional therapeutic breakthroughs." Click Here To Sign Up For Our Health Newsletter The researchers concluded that MDMA showed "enhanced levels of trust, empathy, self-compassion and a 'window of tolerance'" that traditional psychotherapy lacks. Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that "the time is now to address the mental health crisis." He said it is "gratifying" that administration officials value the potential benefits of looking into alternative mental health treatments. Cybin is currently in phase 3 of a study of CYB003, a type of psilocybin that has been granted breakthrough therapy designation by the FDA as an additional treatment for major depressive disorder (MDD). "In Cybin's completed Phase 2 MDD study, long-term efficacy results showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003," said Drysdale. Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News' senior medical analyst, previously interviewed two of the country's top researchers on psychedelics — Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone. "They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses," Siegel told Fox News Digital at the time. "Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts," Siegel added. Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, emphasized it's important to administer psychedelics in a safe setting when treating mental health conditions. For more Health articles, visit "Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials." To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed article source: Psychedelics as potential mental health treatment are explored by Trump administration
Yahoo
2 days ago
- Yahoo
Common menopause medication might prevent breast cancer while treating hot flashes
A drug intended to treat menopause symptoms could double as breast cancer prevention. New research from Northwestern University in Illinois found that Duavee, a Pfizer-made drug, "significantly reduced" breast tissue cell growth, which is a major indicator of cancer progression. A phase 2 clinical trial included 141 post-menopausal women who had been diagnosed with ductal carcinoma in situ (DCIS), also known as stage 0 breast cancer, according to a press release from Northwestern. Prostate Cancer Drug Now Available To More Patients With Aggressive Form Of Disease This non-invasive breast cancer affects more than 60,000 American women each year, often leading to an outcome of invasive breast cancer. The women were separated into two groups — one received Duavee and the other took a placebo for a month before undergoing breast surgery. Read On The Fox News App Duavee is a conjugated estrogen/bazedoxifene (CE/BZA) drug, which combines estrogen with another medication that minimizes the potential harmful side effects of the hormone. "The key takeaway from the study is that CE/BZA slows the growth (proliferation) of cells in milk ducts of DCIS that expressed the estrogen receptor significantly more than placebo," Dr. Swati Kulkarni, lead investigator and professor of breast surgery at Northwestern University Feinberg School of Medicine, told Fox News Digital. Experimental Women's Cancer Drug Boosts Survival Rates In Notable Study Another major finding is that the quality of life did not differ significantly between the two groups, but patients who took the CE/BZA reported fewer hot flashes during the study, she noted. "This would be expected, as the drug is FDA-approved to treat hot flashes." Kulkarni presented the study last week at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The findings are preliminary and have not yet been published in a medical journal. "What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer," said the doctor, who is also a Northwestern Medicine breast surgeon. Women who face a higher risk of breast cancer — including those who have experienced "high-risk lesions" — and who also have menopausal symptoms are most likely to benefit from the drug, according to Kulkarni. "These women are typically advised against standard hormone therapies, leaving them with few menopausal treatment options," the release stated. The researchers said they are "encouraged" by these early results, but more research is required before the medication can be considered for approval as a breast cancer prevention mechanism. "Our findings suggest that CE/BZA may prevent breast cancer, but larger studies with several years of follow-up are needed before we would know this for sure," Kulkarni told Fox News Digital. Dr. Sheheryar Kabraji, chief of breast medicine at the Roswell Park Comprehensive Cancer Center in Buffalo, New York, was not involved in the study but commented on the findings. "While intriguing, this study is highly preliminary, and more research will be needed before we can conclude that conjugated estrogen/bazedoxifene (CD/BZA), a form of the hormone estrogen commonly prescribed to address symptoms of menopause, prevents invasive breast cancer or is effective at reducing cancer risk," she told Fox News Digital. Click Here To Sign Up For Our Health Newsletter Kabraji also noted that the study focused on reducing levels of one specific protein, "which does not always predict reduced recurrence of breast cancer." "This study did not directly show that CE/BZA treatment reduces the risk of DCIS recurrence or development of invasive cancer," she noted. "Importantly, however, patients who received this therapy experienced no worsening of quality of life, and saw improvement in vasomotor symptoms, such as hot flashes. If found to be effective in preventing breast cancer, CE/BZA is likely to have fewer side effects than current medications used for breast cancer prevention." For more Health articles, visit Lead researcher Kulkarni emphasized that this medication is not for the treatment of invasive breast cancer or DCIS. "Right now, we can say that women who are concerned about their risk of developing breast cancer can consider this medication to treat their menopausal symptoms," she article source: Common menopause medication might prevent breast cancer while treating hot flashes
Yahoo
3 days ago
- Yahoo
UnitedHealthcare sues The Guardian for defamation after explosive nursing home story
UnitedHealthcare is suing British newspaper The Guardian for defamation, alleging that the outlet falsely accused them of enticing nursing homes to enroll in a special program that works to restrict medical expenses for elderly patients. "The Guardian knowingly published false and misleading claims about our Institutional Special Needs Program, forcing us to take action to protect the clinician-patient relationship that is crucial for delivering high-quality care. The Guardian refused to engage with the truth and chose instead to print its predetermined narrative," UnitedHealthcare told Fox News Digital in a statement. The Guardian article, published May 21, claimed that UnitedHealthcare is pursuing cost-cutting tactics that jeopardize the health of nursing home patients. The article claims that the health insurance giant provides what amounts to secret bonuses to enroll in a program that stations medical staff that reports directly to UnitedHealthcare, and in practice works to reduce hospitalizations for patients, some of whom allegedly may urgently need the care. Unitedhealthcare Ceo Murder Suspect Luigi Mangione Indicted In New York The article also claims UnitedHealthcare financially entices nursing homes to join their "Institutional Special Needs" program, and allegedly illegally had nursing homes share confidential patient data with the insurer so that it could skirt federal law and market programs to patients – some of whom lack the capacity to make financial decisions on their own – and families. The Guardian also alleged that UnitedHealthcare leaned on nursing home staff to convince patients to sign DNR's, even if they had expressed a desire for all medical options to be used to save their life. "A recent article published by The Guardian presents a narrative built largely on anecdotes rather than facts. It is unfortunate that the article misrepresents a program that, in reality, improves health outcomes for seniors through on-site clinical care, personalized treatment plans, and enhanced coordination among caregivers. We stand firmly behind the integrity of our programs, which consistently receive high satisfaction ratings from our members," UnitedHealthcare said in a statement in response to the article in May. Read On The Fox News App The lawsuit alleged that The Guardian used a "heavily cropped screenshot" of an internal UnitedHealthcare email which they claim, when seen in full, contradicts their reporting. The suit also accuses The Guardian of "gratuitously" linking its report to the assassination of their former CEO Brian Thompson. Unitedhealth Shares Slide As Criminal Probe Report Adds To Investor Fears "The Guardian knew these accusations were false, but published them anyway," the lawsuit stated. The Guardian told Fox News Digital it stood by its reporting. "The Guardian stands by its deeply-sourced, independent reporting, which is based on thousands of corporate and patient records, publicly filed lawsuits, declarations submitted to federal and state agencies, and interviews with more than 20 current and former UnitedHealth employees – as well as statements and information provided by UnitedHealth itself over several weeks. It's outrageous that in response to factual reporting on the practice of secretly paying nursing homes to reduce hospitalizations for vulnerable patients, UnitedHealth is resorting to wildly misleading claims and intimidation tactics via the courts," a representative from The Guardian said. Click To Get The Fox News App When asked by Fox News Digital for clarification regarding the "heavily cropped screenshot," a representative for The Guardian said the image was in fact a "visual illustration" and the so-called missing information was provided "in an on-record comment and a denial from UnitedHealth" in the proceeding paragraph. The Guardian rep also claimed that UnitedHealthcare never asked the press outlet to alter the article source: UnitedHealthcare sues The Guardian for defamation after explosive nursing home story
